This post walks through a real inpatient hematology consult, step by step, to show how experienced consultants organize their thinking over time. The phases are named explicitly to make visible what is usually implicit in practice.
The goal is not to provide an algorithm, but to model judgment as it unfolds.
Opening scenario
You are asked to consult on a hospitalized patient.
A 62-year-old man admitted for an unrelated medical problem was noted to have a falling hemoglobin. He had a prior history of immune-mediated hemolysis, raising concern for recurrence when laboratory testing suggested possible hemolysis.
You are asked to evaluate.
No additional details are provided.
The scenario is deliberately spare. What follows is not a diagnostic walkthrough of this specific case, but a description of how consult reasoning in hemolytic anemia actually unfolds, in stages, over time, and often with incomplete or misleading information.
Companion resources (in development)
Cause-based frameworks and quick-reference tools for common inpatient hematology problems are being developed as part of TBP’s consult reasoning series. They are meant to be used after initial orientation and framing, not in place of them.
How to use this post when you get paged
This is not a diagnostic guide, and it is not meant to be read linearly at the bedside.
Instead, use it as a cognitive checklist at three moments:
- When the page comes in, use Phase 1 to orient to danger, urgency, and asymmetric risk before naming diagnoses.
- When you make your first recommendation, use Phase 2 and 3 to decide what stance you’re taking and how to communicate it clearly under uncertainty.
- When new information arrives, use Phase 4 to recalibrate without rewriting history.
The disease examples that follow are not exhaustive. They are illustrations of how the same reasoning process adapts to different kinds of risk.
The goal is not to tell you what to think, but to help you recognize what kind of thinking the situation demands.
Different consults demand different kinds of thinking
Some hinge on thresholds, where the central question is whether inaction has become more dangerous than action. Others require balancing harms, where no option is safe and the work lies in choosing which risk to accept. Still others require proportionality, where the diagnosis is known and the challenge is matching the mechanism of an intervention to how the disease is behaving over time.
The disease examples that follow are not exhaustive. They are illustrations meant to help you recognize these patterns when you are in the middle of one.
Phase 1: Initial Orientation
(Often begins at the time of the page)
The first phase of consult reasoning is about orientation.
Before naming causes or interpreting laboratory patterns, the consultant identifies a small number of high-yield facts that immediately define urgency, risk, and scope.
In hemolytic anemia, Phase 1 is dominated by danger assessment.
The first question is not what kind of hemolysis is this?
It is: could this be dangerous hemolysis right now?
Key orienting questions
(not ordered by importance)
Is the patient sick?
This deliberately nonspecific question carries enormous weight. This includes hemodynamics, mental status, chest pain, dyspnea, oliguria, neurologic symptoms, or signs of impending decompensation. The answer immediately shapes urgency and tolerance for uncertainty.
Is there evidence of acute organ injury?
Hemolysis becomes dangerous when it occurs as part of a broader pathologic process that is injuring organs or the vasculature—such as thrombotic microangiopathy, severe intravascular hemolysis, or sepsis. Renal failure, neurologic changes, shock, or thrombosis signal that hemolysis is no longer an isolated laboratory finding, but part of a high-risk systemic condition. These features matter more than any single lab value.
How fast is the hemoglobin falling?
A gradual decline over days is very different from an abrupt drop over hours. Trajectory matters more than the absolute number.
Is there active bleeding or another explanation for anemia?
Not all falling hemoglobin reflects hemolysis. Early anchoring on hemolysis without ruling out bleeding is a common error, and can delay lifesaving intervention.
Where is the patient right now?
ICU, general medical floor, post-operative unit, emergency department. Location reflects baseline risk, monitoring capacity, and the plausibility of certain causes.
Is transfusion being considered or required?
Many hemolysis consults are fundamentally about safety and transfusion decisions rather than diagnosis.
At this stage, you are not diagnosing hemolytic anemia.
You are determining whether this could represent life-threatening hemolysis and how urgently you need to act.
By the end of Phase 1, the consultant should be able to say:
- I know whether this is an emergency.
- I know whether organ injury or instability is present.
- I know how urgently I need to act.
- I know the clinical space I’m operating in.
Phase 1 does not determine etiology or mechanism.
It determines tempo and risk tolerance.
Phase 2: Diagnostic Framing
(Choosing a direction of reasoning)
Phase 2 begins once urgency has been established. The patient has been seen, the chart reviewed, and immediate danger—if present—has been addressed.
In this phase, you are not committing to a diagnosis.
You are committing to a way of thinking about the anemia.
Hemolytic anemia is a domain where laboratory noise is common, false positives are frequent, and premature labeling can do harm. Phase 2 is where restraint becomes as important as action.
What informs diagnostic framing
Several elements now come together:
Is hemolysis actually present?
LDH, haptoglobin, and bilirubin are often available early and may suggest hemolysis, but none are definitive in isolation. LDH may reflect tissue injury or infection, haptoglobin may be unreliable in inflammatory states, and bilirubin may rise for reasons unrelated to red cell destruction. These markers inform suspicion, but do not by themselves establish ongoing hemolysis.
Pattern, not single values
True hemolysis declares itself as a pattern across labs, trajectory, and clinical context. Single abnormal results are common and often misleading.
Immune vs non-immune signals
When available, the DAT can help frame immune versus non-immune hemolysis. A positive DAT suggests immune hemolysis, but it may also reflect passive antibodies, recent transfusion, medications, IVIG, or clinically insignificant binding. The test must be interpreted in context, not as a binary answer.
Microangiopathic features
Schistocytes, thrombocytopenia, renal injury, and neurologic findings raise concern for thrombotic microangiopathy, which carries higher urgency and requires immediate intervention.
Clinical trajectory
Is the picture evolving, stabilizing, or resolving without intervention? Time often clarifies what labs obscure.
At this stage, the consultant should be able to say, in broad terms:
- This looks like true hemolysis versus laboratory abnormalities not reflecting ongoing hemolysis.
- If hemolysis is present, this category fits best right now.
- These alternatives are possible but less likely.
- These explanations would surprise me in this context.
That relative ranking—not diagnostic certainty—is the output of Phase 2.
Pretest probabilities, not premature closure
In hemolytic anemia, pretest probabilities are qualitative and provisional.
They determine:
- how aggressively to pursue confirmation,
- how closely to monitor,
- how cautious to be about labeling,
- and what would force reconsideration.
They also determine how new data will be interpreted when it arrives.
The role of high-impact discriminators
Some data carry disproportionate weight once available: peripheral smear review, repeat hemolysis labs over time, DAT interpretation in context, and occasionally specialized testing.
Their absence early is not neglect.
It reflects the reality that hemolysis often declares itself—or dissolves—over time.
What Phase 2 does—and does not—do
Phase 2 does:
- establish whether hemolysis is likely real,
- define the most plausible categories,
- identify what would change your mind.
Phase 2 does not:
- declare a final diagnosis,
- label the patient prematurely,
- or force action unsupported by the evolving pattern.
The product of Phase 2 is a working diagnostic stance, explicit enough to guide care, flexible enough to revise.
Phase 3: Communicating the Consult
(Expressing judgment clearly)
Phase 3 begins once you have a working diagnostic stance.
The task now is communication.
Consult medicine is not only about reasoning well. It is about expressing judgment in a way that is clear, proportional, and trustworthy to the people who need to act on it.
Two audiences, two purposes
Internal communication (within the consult team)
The goal is guidance.
This discussion is used to test interpretation, surface uncertainty, challenge assumptions, and align on concern and plan before speaking externally. This step protects against anchoring, overreaction to noisy labs, and unilateral decision-making.
External communication (to the primary team)
The goal is guidance.
Hemolysis consults are especially prone to diagnostic overreach. Labels like “AIHA,” “TTP,” or even “hemolysis” can propagate quickly, trigger unnecessary treatment, complicate transfusion decisions, and anchor future thinking.
Effective communication focuses on judgment, not terminology.
What effective consult communication sounds like
This often includes:
- what you think is most likely right now,
- what you are most worried about missing,
- what you are actively watching for,
- and what would make you change course.
Clarity matters more than completeness.
Phase 3 communication often occurs before certainty. That is appropriate.
As new information arrives, this communication may need to be revisited. That evolution belongs to the next phase.
Phase 4: Recalibration Over Time
(Revising judgment as new information arrives)
Phase 4 begins as the clinical picture evolves.
In hemolytic anemia, recalibration is often driven not by a single decisive test, but by trajectory:
- hemoglobin stabilizes or continues to fall,
- LDH trends down or remains elevated,
- bilirubin normalizes or rises,
- smear findings evolve—or remain bland.
These changes do not simply add information.
They reshape meaning.
Recalibration is about timing, not better reasoning
Earlier phases rely on what can reasonably be inferred in real time. Phase 4 acknowledges that hemolysis often becomes clearer—or less convincing—with observation.
What matters is not whether the initial stance was provisional—it almost always was—but whether it is revisited honestly.
A recalibration narrative
When I first saw this patient, the concern was for recurrent immune-mediated hemolysis. The hemoglobin was falling, there were laboratory features that raised suspicion for hemolysis, and the patient’s prior history made immune hemolysis a reasonable working hypothesis.
At that point, the stance was deliberately cautious. I told the team that immune hemolysis was possible but unproven, that we should avoid premature labeling, and that the trajectory over the next several days would matter more than any single test.
The key question was not whether immune hemolysis could be named, but whether it would declare itself clinically.
As additional data became available, that declaration did not occur. The DAT returned negative. The hemoglobin stabilized without immune-directed therapy. No new clinical features emerged to support ongoing immune red cell destruction.
What changed was not the framework, but the weight of the hypothesis.
Internally, we revisited the working stance. A diagnosis that had been plausible early now carried less explanatory power. The prior history that initially raised concern no longer justified anchoring the case. Immune hemolysis moved from “possible and important to watch” to “unlikely to be driving the current picture.”
Externally, we updated the team. The message was not that the initial concern had been misguided, but that it had been appropriate given what was known at the time, and that the evolving data now supported letting go of that label.
The important move was not identifying the correct diagnosis at the outset.
It was knowing when immune hemolysis no longer fit—and being willing to release the label.
Communication revisited
As the picture evolves:
- internal discussion recalibrates concern,
- external communication adjusts recommendations,
- and diagnostic labels are strengthened or withdrawn accordingly.
Letting go of a diagnosis is not indecision.
It is disciplined reassessment.
What Phase 4 demands of the consultant
Phase 4 asks the consultant to revise judgment without rewriting history.
Earlier caution may have been necessary. Later restraint may be equally so. Good consult practice requires being able to explain both.
The best consultants are not those who commit early and never revise, but those who can say:
“This was plausible when we saw it. It no longer is. And here is why.”
Closing reflection
Across these four phases, hemolytic anemia reveals a distinct consult rhythm.
Laboratory signals are noisy.
False positives are common.
Restraint matters as much as action.
Time often clarifies what tests obscure.
Urgency is defined before diagnosis.
Direction is chosen before certainty.
Judgment is communicated before completion.
And conclusions are revised as reality evolves.
What matters is not perfection at any single moment, but the ability to think, communicate, and recalibrate well over time.
That process—made visible here—is how consult medicine is actually practiced.